SciELO - Scientific Electronic Library Online

vol.27 issue9Kidney transplantation: Techique and complicationsalpha1-adrenergic receptors categorisation in the detrusor of patients with obstructive BPH: Early study in experimental models author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Actas Urológicas Españolas

Print version ISSN 0210-4806


LORENTE, J.A. et al. The effect of long-term neoadjuvant combined androgen blockade withdrawal therapy: Comparative study with standard therapy. Actas Urol Esp [online]. 2003, vol.27, n.9, pp.678-683. ISSN 0210-4806.

INTRODUCTION: Radical prostatectomy is considered as a curative treatment option in clinically localised prostate cancer patients. Therapy failure is related to positive surgical margins and/or extracapsular extension. The use of neoadjuvant combined androgen blockade (CAB) withdrawal therapy, mainly in cT2 disease, has been shown to decrease positive margin rates. However, CAB therapy remains controversial since there is no proof that this approach confers any benefit in relation to biochemical and clinical disease-free survival. Increasing negatives surgical margins and lower tumour volume (TV) with prolonged CAB therapy has been recently reported. AIM: To analyse the effect of 6 months neoadjuvant CAB therapy in front of 3 months in clinically localised prostate cancer patients submitted to radical prostatectomy. PATIENTS AND METHODS: The pathological stage and TV in forty-two patients treated by 6 months in front of thirty-four patients treated by 3 months were studied. The relationship of clinical stage and initial PSA concentration were analysed. RESULTS: TV was significantly lower in 6 months treated patients (0.97 cc vs. 0.48 cc, p=0.05). The lowest TV was observed in cT1 patients, but significant differences only were observed in cT2 (1.5 cc vs. 0.86 cc, p=0.04). No relationship between TV and PSA was obtained. No differences in the incidence of organ-confined disease were seen depending of the CAB length (47% vs. 43%, p=NS). However, increasing incidence of specimen-confined disease was observed in 6 months treated patients (56% vs. 74%, p=0.05). CONCLUSION: The duration of neoadjuvant CAB can affect both TV and surgical margin status. Lower TV and increasing incidence of specimen-confined disease with 6 months CAB treatment were observed. Patients with palpable disease may be more benefited by this treatment option.

Keywords : Prostate cancer; Combined androgen blockade; Neoadjuvant therapy.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License